Trial reportArchives of dermatological research2025
Comparative study of different treatment modalities for melasma: introducing a novel nanotechnology-based tranexamic acid microemulsion.
Trial report in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Melasma therapy remains challenging due to limited effectiveness, side effects, and relapses. Topical tranexamic acid (TXA) is promising but requires further research to optimize its formulation. Alongside the therapeutic benefit of fractional CO2 laser (FCL) in melasma, FCL and microneedling (MN) are recognized methods for transepidermal drug delivery. Nanotechnology-based topicals can enhance drug penetration and reduce side effects. Objectives were to evaluate and compare the effectiveness of combined FCL- or MN-assisted transepidermal delivery of TXA 3% gel and FCL monotherapy versus nanotechnology-based TXA 1% microemulsion monotherapy in melasma treatment. Fifty-two melasma females were divided randomly into three groups (A, B & C) for a five-month treatment. Group A (n = 20), using a split-face design, received FCL on the right side (A1) and MN on the left (A2), both with TXA 3% gel applied post-session and daily. Group B (n = 21), also with a split-face design, received FCL with TXA 3% gel post-session only on the right side (B1), while the left side (B2) received FCL alone. Group C (n = 11) received TXA 1% microemulsion daily for the whole face. Evaluations included clinical, dermoscopic, and immunohistochemical SOX10 assessments, with a three-month follow-up. All groups showed a significant reduction of Hemi Melasma Area and Severity Index (Hemi-MASI), dermoscopic, and SOX10 immunoreactivity scores. Groups A1, A2, and C exhibited greater improvement compared to B1 and B2. No recurrence occurred during follow-up. Concluding that TXA 1% microemulsion is effective and safe, procedure-free monotherapy with outcomes comparable to FCL- and MN-assisted TXA 3% gel delivery for melasma.
Indexed as
Identifiers
40455320What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.